Biomarkers for risk stratification of malignancy-prone precancerous conditions: focusing on gastric intestinal metaplasia.
- 1State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
- 2Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Abstract
Gastric cancer (GC) develops as a long-term process from the combined effects of multiple risk factors, during which genetic and epigenetic changes accumulate. The Correa cascade delineates the sequential transformation from normal gastric mucosa to GC, within which gastric intestinal metaplasia (GIM) represents a pivotal precancerous condition. Notably, incomplete GIM (IIM) carries a substantially increased risk of neoplastic progression compared with complete IM (CIM), with a pooled relative risk of 4.96 for gastric cancer; the sulfomucin-expressing type III subtype shows an even stronger association with cancer/dysplasia, with a pooled relative risk of 6.27 compared with type I/II IM. Endoscopy provides visualization of macroscopic mucosal alterations, whereas risk stratification at the histological and molecular levels requires the application of validated biomarkers. Although multiple molecular indicators have been reported in GIM, an integrated and clinically oriented synthesis of these markers is still lacking. This review summarizes recent advances in tissue- and serum-derived biomarkers that may help identify high-risk GIM. Tissue biomarkers reflect either the upstream molecular drivers of metaplastic transformation or the downstream effectors of epithelial reprogramming, such as aberrant oncogene activation, epithelial differentiation markers, transcription factors, trefoil factor family (TFF) members, and SPEM-associated proteins. Additionally, circulating biomarkers, including established serum indices and novel omics- and epigenetic-based signatures, offer non-invasive potential for early GC prediction. Incorporating candidate biomarkers into clinical workflows may enhance early detection and optimize surveillance strategies for patients with GIM. We also distinguishes phenotype-defining markers from candidate progression-risk markers in GIM. The next step is to test whether integrated tissue biomarker panels improve prediction of dysplasia or GC on top of OLGIM, EGGIM, and clinical risk factors in longitudinal cohorts.
Related
- Metaplasia intestinal gástrica: actualización en epidemiología, diagnóstico, estratificación del riesgo y manejo clínico Gastric Intestinal Metaplasia: an Update on Epidemiology, Diagnosis, Risk Stratification, and Clinical Management
- Preoperative Malignancy Risk Stratification in Bethesda IV Thyroid Nodules Using Integrated Clinical, Ultrasonographic, and Biochemical Parameters in Surgical Oncology Practice.
- Development and internal validation of an interpretable mammography-based model for malignancy risk stratification in BI-RADS 4 breast lesions
- Toward Precision Colorectal Cancer Screening: Integrating Clinical Risk Stratification, Molecular Biomarkers, and Artificial Intelligence
- Core needle biopsy washout biomarkers combined with ultrasound for preoperative axillary risk stratification in breast cancer: a retrospective nomogram study with temporal validation
BibTeX
@article{zhang2026biomarkers,
title = {{Biomarkers for risk stratification of malignancy-prone precancerous conditions: focusing on gastric intestinal metaplasia.}},
author = {Zhongyang Zhang and Xianchun Gao and Reyila Abudurousuli and Jun Yu and Dai Zhang and Peng Li and Yongzhan Nie},
journal = {Medical review (2021)},
year = {2026},
month = jul,
doi = {10.1515/mr-2026-0022},
url = {https://europepmc.org/article/MED/42923773},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Biomarkers for risk stratification of malignancy-prone precancerous conditions: focusing on gastric intestinal metaplasia.
AU - Zhongyang Zhang
AU - Xianchun Gao
AU - Reyila Abudurousuli
AU - Jun Yu
AU - Dai Zhang
AU - Peng Li
AU - Yongzhan Nie
PY - 2026
DA - 2026/07/01
JO - Medical review (2021)
DO - 10.1515/mr-2026-0022
UR - https://europepmc.org/article/MED/42923773
AB - Gastric cancer (GC) develops as a long-term process from the combined effects of multiple risk factors, during which genetic and epigenetic changes accumulate. The Correa cascade delineates the sequential transformation from normal gastric mucosa to GC, within which gastric intestinal metaplasia (GIM) represents a pivotal precancerous condition. Notably, incomplete GIM (IIM) carries a substantially increased risk of neoplastic progression compared with complete IM (CIM), with a pooled relative risk of 4.96 for gastric cancer; the sulfomucin-expressing type III subtype shows an even stronger association with cancer/dysplasia, with a pooled relative risk of 6.27 compared with type I/II IM. Endoscopy provides visualization of macroscopic mucosal alterations, whereas risk stratification at the histological and molecular levels requires the application of validated biomarkers. Although multiple molecular indicators have been reported in GIM, an integrated and clinically oriented synthesis of these markers is still lacking. This review summarizes recent advances in tissue- and serum-derived biomarkers that may help identify high-risk GIM. Tissue biomarkers reflect either the upstream molecular drivers of metaplastic transformation or the downstream effectors of epithelial reprogramming, such as aberrant oncogene activation, epithelial differentiation markers, transcription factors, trefoil factor family (TFF) members, and SPEM-associated proteins. Additionally, circulating biomarkers, including established serum indices and novel omics- and epigenetic-based signatures, offer non-invasive potential for early GC prediction. Incorporating candidate biomarkers into clinical workflows may enhance early detection and optimize surveillance strategies for patients with GIM. We also distinguishes phenotype-defining markers from candidate progression-risk markers in GIM. The next step is to test whether integrated tissue biomarker panels improve prediction of dysplasia or GC on top of OLGIM, EGGIM, and clinical risk factors in longitudinal cohorts.
SN - 2097-0773
SN - 2749-9642
ER -